Tirzepatide vs Semaglutide Cardiovascular Outcomes in 2026

Why This Study Matters

The cardiovascular evidence gap between semaglutide and tirzepatide has become one of the central questions in the incretin category. Semaglutide's SELECT trial showed cardiovascular event reduction in adults with established cardiovascular disease and overweight or obesity but without diabetes. Tirzepatide has stronger weight-loss data in obesity trials, but the equivalent non-diabetic cardiovascular outcomes answer is still being tested in SURMOUNT-MMO.

That leaves a practical comparison unresolved: if both drugs are already used in clinical practice for overlapping obesity populations, what happens when new users are followed in real-world claims data? NCT07619508 is designed to emulate that target trial. It compares new users of tirzepatide with new users of injectable semaglutide and follows major cardiovascular outcomes after the first prescription fill.

The study's framing is careful. It acknowledges that randomization cannot be achieved in healthcare claims data, so measured baseline differences are handled through statistical covariate balancing. That makes the study useful for comparative-effectiveness signal generation, but not equivalent to a randomized cardiovascular outcomes trial.

SELECT, SURMOUNT-MMO, and the Evidence Gap

SELECT is the anchor semaglutide cardiovascular outcomes trial in non-diabetic obesity. It enrolled adults with established cardiovascular disease and overweight or obesity, without diabetes, and tested semaglutide 2.4 mg against placebo. The result established semaglutide as the first GLP-1 obesity therapy with a cardiovascular event-reduction dataset in that population.

Tirzepatide's closest equivalent is SURMOUNT-MMO, a placebo-controlled cardiovascular outcomes trial in adults with obesity or overweight and no diabetes. NCT07619508 explicitly notes that SURMOUNT-MMO results are expected in late 2027. Until that readout arrives, the comparative question sits between two evidence types: completed semaglutide CVOT data and observational real-world tirzepatide-vs-semaglutide emulation.

For broader efficacy comparisons, see our retatrutide vs tirzepatide vs CagriSema guide. For injectable access, pricing, and UAE context, see the weight loss injections comparison guide.

What the Endpoints Measure

The primary endpoint is a composite of all-cause mortality, myocardial infarction, or stroke. That is a tighter cardiovascular outcome than weight-loss percentage or A1C change because it asks whether the downstream event curve differs between treatment groups.

Secondary endpoints break out the individual components of the primary endpoint and expand the cardiovascular lens to hospitalization for unstable angina, coronary revascularization, and hospitalization for heart failure. Safety outcomes include urinary tract infections, serious infections, and gastrointestinal adverse events. The registration also includes negative-control outcomes such as hernia and lumbar radiculopathy, which help test whether residual confounding is distorting the signal.

How to Read the Study Conservatively

The most important limitation is design. NCT07619508 is not randomizing participants to tirzepatide or semaglutide. It is using healthcare claims data, then matching or balancing measured covariates to approximate a target trial. This can reduce measured confounding, but it cannot eliminate unmeasured confounding.

Practical examples matter. People started on tirzepatide versus semaglutide may differ by insurance coverage, prescriber preference, disease severity, prior medication history, cost tolerance, pharmacy availability, or time period. The study design attempts to proxy the most important inclusion, exclusion, exposure, and outcome rules, but claims data do not perfectly reproduce trial adjudication, clinical measurements, body-composition endpoints, or medication adherence.

The right conclusion is not "tirzepatide beats semaglutide" or the reverse. The right conclusion is: a major research group has now registered a large comparative-effectiveness study that will help triangulate the cardiovascular question before tirzepatide's randomized non-diabetic CVOT reads out.

What to Watch Next

There are three watch points. First, whether NCT07619508 posts results or produces a peer-reviewed manuscript, and whether the effect direction matches SELECT-era expectations. Second, whether SURMOUNT-MMO confirms a cardiovascular benefit for tirzepatide in non-diabetic obesity. Third, whether future head-to-head designs move beyond claims data into purpose-built randomized or deep-phenotyping trials.

One adjacent study already moves in that direction: COMPARE-AT (NCT07589322), an open-label tirzepatide-vs-semaglutide trial measuring body composition, liver fat, bone turnover, AI-ECG cardiometabolic risk, and multi-omics signatures. Together, these studies show that the comparison is shifting from "which drug loses more weight?" toward "which drug changes cardiovascular and tissue-level risk most convincingly?"